Fractionated photothermal antitumor therapy with multidye nanoparticles

Gutwein, Luke G.; Singh, Amit; Hahn, Martin W.; Rule, Michael C.; Knapik, Jacquelyn A.; Moudgil, Brij M.; Brown, Scott C.; Grobmyer, Stephen R.

doi:10.2147/ijn.s26468

Cited by 9 publications

(4 citation statements)

References 15 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are in contrast to another study conducting fractionated PTT in mice which reported great response after four treatments using a laser intensity even lower than the one used in this study, although in smaller tumors 23. Hence, there are probably many factors that can contribute to the treatment outcome, such as choice of photothermal agent, tumor size at initiation of treatment, laser dose, and treatment protocol.…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

<p>Fractionated photothermal therapy in a murine tumor model: comparison with single dose</p>

Simón

Nørregaard

Jørgensen

et al. 2019

IJN

View full text Add to dashboard Cite

Purpose: Photothermal therapy (PTT) exploits the light-absorbing properties of nanomaterials such as silica-gold nanoshells (NS) to inflict tumor death through local hyperthermia. However, in in vivo studies of PTT, the heat distribution is often found to be heterogeneous throughout the tumor volume, which leaves parts of the tumor untreated and impairs the overall treatment outcome. As this challenges PTT as a one-dose therapy, this study here investigates if giving the treatment repeatedly, ie, fractionated PTT, increases the efficacy in mice bearing subcutaneous tumors. Methods: The NS heating properties were first optimized in vitro and in vivo. Two fractionated PTT protocols, consisting of two and four laser treatments, respectively, were developed and applied in a murine subcutaneous colorectal tumor model. The efficacy of the two fractionated protocols was evaluated both by longitudinal monitoring of tumor growth and, at an early time point, by positron emission tomography (PET) imaging of 18 F-labeled glucose analog 18 F-FDG. Results: Overall, there were no significant differences in tumor growth and survival between groups of mice receiving single-dose PTT and fractionated PTT in our study. Nonetheless, some animals did experience inhibited tumor growth or even complete tumor disappearance due to fractionated PTT, and these animals also showed a significant decrease in tumor uptake of 18 F-FDG after therapy. Conclusion: This study only found an effect of giving PTT to tumors in fractions compared to a single-dose approach in a few animals. However, many factors can affect the outcome of PTT, and reliable tools for optimization of treatment protocol are needed. Despite the modest treatment effect, our results indicate that 18 F-FDG PET/CT imaging can be useful to guide the number of treatment sessions necessary.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…One mouse in the four-treatment group even experienced complete tumor regression. The group sizes in this study were comparable to other studies on PTT and fractionated therapy 23,24. However, it should be noted that at these group sizes the risk of type II statistical errors make detection of smaller survival benefits difficult to show.…”

Section: Discussionsupporting

confidence: 78%

<p>Fractionated photothermal therapy in a murine tumor model: comparison with single dose</p>

Simón

Nørregaard

Jørgensen

et al. 2019

IJN

View full text Add to dashboard Cite

show abstract

“…Another strategy is to give the treatment in low-dose fractions instead of a single dose, thereby killing cancer cells that survived during the first treatment in following treatments and avoiding surface overheating [ 163 , 164 , 165 ]. Simón et al applied a fractionated PTT, using silica–gold nanoshells (NS), instead of one-dose therapy to increase the efficacy of photothermal treatment of subcutaneous colon carcinoma tumors in mice [ 166 ].…”

Section: Other Strategies For Pain Management In Pttmentioning

confidence: 99%

Nanoparticle-Mediated Photothermal Therapy Limitation in Clinical Applications Regarding Pain Management

et al. 2022

View full text Add to dashboard Cite

The development of new effective cancer treatment methods has attracted much attention, mainly due to the limited efficacy and considerable side effects of currently used cancer treatment methods such as radiation therapy and chemotherapy. Photothermal therapy based on the use of plasmonically resonant metallic nanoparticles has emerged as a promising technique to eradicate cancer cells selectively. In this method, plasmonic nanoparticles are first preferentially uptaken by a tumor and then selectively heated by exposure to laser radiation with a specific plasmonic resonant wavelength, to destroy the tumor whilst minimizing damage to adjacent normal tissue. However, several parameters can limit the effectiveness of photothermal therapy, resulting in insufficient heating and potentially leading to cancer recurrence. One of these parameters is the patient’s pain sensation during the treatment, if this is performed without use of anesthetic. Pain can restrict the level of applicable laser radiation, cause an interruption to the treatment course and, as such, affect its efficacy, as well as leading to a negative patient experience and consequential general population hesitancy to this type of therapy. Since having a comfortable and painless procedure is one of the important treatment goals in the clinic, along with its high effectiveness, and due to the relatively low number of studies devoted to this specific topic, we have compiled this review. Moreover, non-invasive and painless methods for temperature measurement during photothermal therapy (PTT), such as Raman spectroscopy and nanothermometry, will be discussed in the following. Here, we firstly outline the physical phenomena underlying the photothermal therapy, and then discuss studies devoted to photothermal cancer treatment concerning pain management and pathways for improved efficiency of photothermal therapy whilst minimizing pain experienced by the patient.

show abstract

“…Some additional nanomaterials used in conjunction with photothermal therapy include silicon nanowires with gold nanoparticles 65 ; CuS nanoparticles 66 - 69 ; multidye mesoporous silica with silane-conjugated heptamethine cyanine dye loaded with silicon 2,3-napthalocyanine dihydroxide dye 70 ; single walled carbon nanotubes 71 ; porous silicon nanoparticles 72 ; NIR resonant silica core, gold shell, PEG nanoparticles 73 ; chitosan-coated triangular silver nanoparticles 74 ; and palladium nanosheets 75 , 76 .…”

Section: Phototriggered Theranostics For Cancer Applicationsmentioning

confidence: 99%

Remotely Triggered Nano-Theranostics For Cancer Applications

Sneider¹,

VanDyke²,

Paliwal³

et al. 2017

Nanotheranostics

View full text Add to dashboard Cite

Nanotechnology has enabled the development of smart theranostic platforms that can concurrently diagnose disease, start primary treatment, monitor response, and, if required, initiate secondary treatments. Recent in vivo experiments demonstrate the promise of using theranostics in the clinic. In this paper, we review the use of remotely triggered theranostic nanoparticles for cancer applications, focusing heavily on advances in the past five years. Remote triggering mechanisms covered include photodynamic, photothermal, phototriggered chemotherapeutic release, ultrasound, electro-thermal, magneto-thermal, X-ray, and radiofrequency therapies. Each section includes a brief overview of the triggering mechanism and summarizes the variety of nanoparticles employed in each method. Emphasis in each category is placed on nano-theranostics with in vivo success. Some of the nanotheranostic platforms highlighted include photoactivatable multi-inhibitor nanoliposomes, plasmonic nanobubbles, reduced graphene oxide-iron oxide nanoparticles, photoswitching nanoparticles, multispectral optoacoustic tomography using indocyanine green, low temperature sensitive liposomes, and receptor-targeted iron oxide nanoparticles loaded with gemcitabine. The studies reviewed here provide strong evidence that the field of nanotheranostics is rapidly evolving. Such nanoplatforms may soon enable unique advances in the clinical management of cancer. However, reproducibility in the synthesis procedures of such “smart” platforms that lend themselves to easy scale-up in their manufacturing, as well as the development of new and improved models of cancer that are more predictive of human responses, need to happen soon for this field to make a rapid clinical impact.

show abstract

Fractionated photothermal antitumor therapy with multidye nanoparticles

Cited by 9 publications

References 15 publications

<p>Fractionated photothermal therapy in a murine tumor model: comparison with single dose</p>

<p>Fractionated photothermal therapy in a murine tumor model: comparison with single dose</p>

Nanoparticle-Mediated Photothermal Therapy Limitation in Clinical Applications Regarding Pain Management

Remotely Triggered Nano-Theranostics For Cancer Applications

Contact Info

Product

Resources

About